PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Adavosertib

Drugs in development · updated 30 October 2026

Adavosertib: clinical trials and development status

Other names and codes: AZD1775

NLM verified identityNot approved in the USNo EMA authorisation

As of 30 October 2026 Adavosertib is in 13 active clinical trials (recruiting or ongoing, phases I–III) for 32 diseases. The most advanced phase is II.

13Active trials
IIMost advanced phase
32Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Adavosertib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 32 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Fallopian tube neoplasmII3NCT02101775
Ovarian neoplasmII3NCT02465060
Hematologic neoplasmII2NCT04439227
LymphomaII2NCT04439227
MetastasisII2NCT03284385
Multiple myelomaII2NCT04439227
NeoplasmII2NCT02101775
Prostatic NeoplasmsII2NCT02465060
Uterine neoplasmII2NCT02465060
Bladder neoplasmII1NCT02465060
Breast neoplasmII1NCT02465060
Brenner tumorII1NCT02101775
Colonic neoplasmII1NCT02465060
Colorectal neoplasmII1NCT02465060
Endometrial neoplasmII1NCT02465060
Esophageal neoplasmII1NCT02465060
GliomaII1NCT02465060
Hepatocellular carcinomaII1NCT02465060
Lung neoplasmII1NCT02465060
MelanomaII1NCT02465060
Pancreatic neoplasmII1NCT02465060
Rectal neoplasmII1NCT02465060
Renal cell carcinomaII1NCT03284385
Stomach neoplasmII1NCT02465060
Thyroid neoplasmII1NCT02465060
Triple-negative breast neoplasmII1NCT03330847
Uterine cervix neoplasmII1NCT02465060
Brain NeoplasmsI1NCT04460937
Esophageal squamous cell carcinomaI1NCT04460937
Esophagus adenocarcinomaI1NCT04460937

Everything on Adavosertib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch